Skip to content
Subscriber Only

Pfizer Forecast Falls Short on Patent Expiration, Currency

Updated on

Pfizer Inc., the biggest U.S. drugmaker, forecast a decline in sales this year as patent expirations and a stronger dollar weigh on revenue.

Sales will reach $44.5 billion to $46.5 billion this year, down from $49.6 billion in 2014, Pfizer said in a statement Tuesday. Analysts had estimated $47.6 billion on average. The company’s projection includes a $3.5 billion impact from the loss of exclusivity on some products and $2.8 billion related to foreign-exchange rates.